The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases

Hunjoo Ha, Eun Y. Oh, Hi B. Lee

Research output: Contribution to journalReview articlepeer-review

114 Scopus citations

Abstract

The 50 kDa glycoprotein plasminogen activator inhibitor 1 (PAI-1) is the major physiological inhibitor of tissue-type and urokinase-type plasminogen activator. These two molecules convert inactive plasminogen into its fibrin-degrading form, plasmin. Plasma and tissue concentrations of PAI-1 are extremely low under normal circumstances but increase under pathologic conditions. This increase is mediated by many factors, including reactive oxygen species. Increased PAI-1 activity is associated with an increased risk of ischemic cardiovascular events and tissue fibrosis. Whereas the antifibrinolytic property of PAI-1 derives mainly from its inhibition of serine proteases, its profibrotic actions seem to derive from a capacity to stimulate interstitial macrophage recruitment and increase transcription of profibrotic genes, as well as from inhibition of serine proteases. Despite studies in mice that lack or overexpress PAI-1, the biological effects of this molecule in humans remain incompletely understood because of the complexity of the PAI-1-plasminogen- activator-plasmin system. The cardioprotective and renoprotective properties of some currently available drugs might be attributable in part to inhibition of PAI-1. The development of an orally active, high-affinity PAI-1 inhibitor will provide a potentially important pharmacological tool for further investigation of the role of PAI-1 and might offer a novel therapeutic strategy in renal and cardiovascular diseases.

Original languageEnglish
Pages (from-to)203-211
Number of pages9
JournalNature Reviews Nephrology
Volume5
Issue number4
DOIs
StatePublished - Apr 2009

Fingerprint

Dive into the research topics of 'The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases'. Together they form a unique fingerprint.

Cite this